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resembling that seen in congenital disorders
of glycosylation
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Background: Congenital disorders of glycosylation (CDGs) are inherited diseases caused by glycosylation defects.
Incorrectly glycosylated proteins induce protein misfolding and endoplasmic reticulum (ER) stress. The most common
form of CDG, PMM2-CDG, is caused by deficiency in the cytosolic enzyme phosphomannomutase 2 (PMM2). Patients
with PMM2-CDG exhibit a significantly reduced number of cerebellar Purkinje cells and granule cells. The molecular
mechanism underlying the specific cerebellar neurodegeneration in PMM2-CDG, however, remains elusive.
Results: Herein, we report that cerebellar granule cells (CGCs) are more sensitive to tunicamycin (TM)-induced
inhibition of total N-glycan synthesis than cortical neurons (CNs). When glycan synthesis was inhibited to a comparable
degree, CGCs exhibited more cell death than CNs. Furthermore, downregulation of PMM2 caused more CGCs to die
than CNs. Importantly, we found that upon PMM2 downregulation or TM treatment, ER-stress response proteins were
elevated less significantly in CGCs than in CNs, with the GRP78/BiP level showing the most significant difference. We
further demonstrate that overexpression of GRP78/BiP rescues the death of CGCs resulting from either TM-treatment or
PMM2 downregulation.
Conclusions: Our results indicate that the selective susceptibility of cerebellar neurons to N-glycosylation defects is
due to these neurons’ inefficient response to ER stress, providing important insight into the mechanisms of selective
neurodegeneration observed in CDG patients.
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Congenital disorders of glycosylation (CDGs) are inher-
ited autosomal recessive disorders caused by defects in
the glycosylation pathway, and display a broad spectrum
of clinical features such as psychomotor retardation,
hypotonia, intractable seizures, stroke-like episodes, in-
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reproduction in any medium, provided the orfailure to thrive [1,2]. There are about 70 reported gene
defects that affect N-linked and/or O-linked glycosyla-
tion pathways, resulting in truncated or completely
missing glycans and leading to the pathogenesis of
CDGs. Mutations in the PMM2 gene that encodes the
cytosolic enzyme phosphomannomutase 2 (PMM2) re-
sult in the most common and well-known CDG,
PMM2-CDG (or CDG-Ia), of which more than 800 cases
have been reported worldwide. The physiological func-
tion of PMM2 is to convert mannose 6-phosphate to
mannose 1-phosphate and a complete loss of PMM2 can
cause lethality in yeast, mice and presumably humans.
Cerebellar atrophy, or hypoplasia, is a major and nearly
constant feature of PMM2-CDG [3-5]. Histological and. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from PMM2-CDG patients show partial atrophy of cere-
bellar folia with a severe loss of Purkinje cells and gran-
ule cells, and various morphological changes in the
remaining Purkinje cells. However, it is unclear why
cerebellar neurons are selectively susceptible to glycosyl-
ation defects in these patients.
Altered glycosylation in CDG leads to protein misfold-
ing and induces stress in the endoplasmic reticulum
(ER). ER stress is caused by an imbalance between the
cellular demand for ER function and ER capacity [6-8].
Multiple physiological or pathological conditions that
affect protein folding and/or calcium homeostasis can
cause ER stress. These conditions include underglycosy-
lation of glycoconjugates, glucose starvation, elevated
protein synthesis and secretion, and failure of protein
folding, transport or degradation. After sensing ER
stress, cells activate the unfolded protein response (UPR)
pathway to alleviate the problem and maintain function
through two adaptive mechanisms: (i) increasing the
folding capacity of the ER through upregulating the
genes encoding molecular chaperones and foldases [9]
and (ii) decreasing the protein burden on the ER
through inhibition of protein synthesis and enhancing
ER-associated degradation of misfolded proteins [10].
Thus, UPR enables the cells to reduce the misfolded
protein load on the ER and promotes protein folding, se-
cretion and degradation [6,11]. Genome-wide analysis of
the UPR in fibroblasts from CDG patients show that CDG
cells have chronic ER stress, and that the genes encoding
components of the UPR are moderately induced [12].
Herein, we studied the molecular mechanism under-
lying the selective vulnerability of cerebellar neurons in
PMM2-CDG. Our results revealed that murine cerebel-
lar granule cells (CGCs) are much more sensitive to gly-
cosylation defects and associated cell death than cortical
neurons (CNs), and that a less efficient response to gly-
cosylation disruption-induced ER stress in CGCs may be
responsible for their selective vulnerability and neurode-
generation in the patients.
Results
The nucleoside antibiotic tunicamycin (TM) is a specific
inhibitor of N-linked glycosylation and has been widely
used to study glycosylation defects [13,14]. Herein, we
treated murine primary CGCs and CNs with various
concentrations of TM and measured glycan synthesis in
these neurons. The results showed that TM treatments
inhibited glycan synthesis in both CGCs and CNs in a
dose-dependent manner (Figure 1A). However, treat-
ments with the same concentrations of TM resulted in a
more dramatic reduction in glycan synthesis in CGCs
than in CNs. Treatment with 1 ng/mL TM in CGCs led
to a 25% reduction in glycan synthesis, whereas 25 ng/mLTM was required in CNs for the same level of reduction
(Figure 1A). These results suggest that glycosylation in
CGCs is more sensitive to TM than that in CNs.
We next studied the death of CGCs and CNs in re-
sponse to TM treatments. Similar to glycan synthesis re-
duction, TM treatments induced cell death in CGCs and
CNs in a dose-dependent manner (Figure 1B). However,
low doses of TM (1–5 ng/mL) already induced signifi-
cant death in CGCs, whereas only high doses of TM
(25–50 ng/mL) caused significant death in CNs. More-
over, when glycan synthesis was inhibited to a compar-
able level (25%) (i.e., 1 ng/mL and 25 ng/mL TM for
CGCs and CNs, respectively), cell death in CGCs was
much greater than in CNs (Figure 1C) and the difference
was statistically significant (Figure 1B).
To explore the role of PMM2 in specific cerebellar
neurodegeneration in CDG, we downregulated PMM2
expression using three different shRNAs in murine pri-
mary CGCs and CNs. When the levels of PMM2 protein
were reduced in CNs and CGCs (Figure 2A), both types
of cells underwent marked death (Figure 2B,C). How-
ever, the death rate in CGCs (~60-70%) was significantly
higher than that in CNs (~20-30%) (Figure 2B,C), even
when the protein level of PMM2 (using shRNA1,
Figure 2A, lanes 2 vs 6) and the enzymatic activity of
PMM (Figure 2D) were reduced to a similar extent in
CNs and CGCs. These results suggest that CGCs are
more vulnerable to neurodegeneration than CNs in re-
sponse to PMM2 deficiency.
N-linked oligosaccharides are critical for protein fold-
ing [15,16]. It is well established that underglycosylation
of glycoproteins causes protein misfolding and ER stress.
Therefore, we studied the expression levels of ER stress-
response proteins. We found that when the protein level
of PMM2 (Figure 2A, lanes 2 vs 6) and the enzymatic
activity of PMM (Figure 2D) were downregulated to a
similar extent by shRNA1, the protein level of GRP78/
BiP (glucose regulated protein/binding immunoglobulin
protein) was increased in both CGCs and CNs (Figure 3A,C).
However, the increase of GRP78/BiP level in CGCs (1.77
folds) was significantly lower than that in CNs (3.42 folds)
(Figure 3C). Similarly, when cells were treated with TM,
the protein level of GRP78/BiP was increased in both
CGCs and CNs in a dose dependent manner (Figure 3B;
Additional file 1: Figure S1). However, when glycan
synthesis was inhibited to a comparable level (25%)
(Figure 1A), the increase of GRP78/BiP level in CGCs
treated with 1 ng/mL TM (2.17 folds) was significantly
lower than that in CNs treated with 25 ng/mL TM (10.96
folds) (Figure 3D).
We also compared changes in the expression level of
other ER stress-response proteins, including PDI, IRE-
1α, and the heat shock proteins HSP60, HSP70, and
HSP90, between CGCs and CNs. We found that when
Figure 1 CGCs are more sensitive to TM-mediated neurotoxicity than CNs. A. Murine primary CGCs and CNs were exposed to various
concentrations of TM for 3 d. Newly synthesized glycans were labeled for 20 h with [3H]-mannose and assayed, n = 3, error bars: standard
deviation. Synthesis of glycans was decreased considerably more in CGCs than in CNs. Treatment with 1 ng/mL TM in CGCs resulted in a
reduction in glycan synthesis (25%) comparable to that by treatment with 25 ng/mL of TM in CNs (indicated by dashed lines). B. CGCs and CNs
were exposed to various concentrations of TM for 3 d. Cells were then subjected to a TUNEL assay to quantify cell death. TM treatments induced
cell death in both CNs and CGCs. **: p < 0.01; ***: p < 0.001. When glycan synthesis was inhibited at a comparable level (25%), cell death in CGCs
treated with 1 ng/mL TM was significantly more than that of CNs treated with 25 ng/mL TM. #: p < 0.01. C. Representative TUNEL staining of CNs
and CGCs upon treatment with 25 and 1 ng/mL TM, respectively. Dying cells were stained in green and cell nuclei were stained in blue (with
DAPI). TUNEL staining of cells without TM treatment (TM0) was used as a control. Please note that during cell culturing, the seeding densities for
CNs and CGCs were different.
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pression levels of these proteins were increased to vary-
ing degrees. The increases in HSP60, PDI and IRE-1α
showed statistical significance (Figure 3A,C). However,
downregulation of PMM2 had no significant effect on
these proteins in CGCs (Figure 3A,C). When CNs were
treated with TM, we found that the levels of all these
proteins were elevated in a dose-dependent manner,
whereas only the levels of PDI and IRE-1α were increased
in CGCs (Figure 3B; Additional file 1: Figure S1). In
addition, the protein level increases in CGCs treated with
1 ng/mL TM were lower than those in CNs treated with
25 ng/mL TM, with the differences in HSP60 (1.09 folds
vs. 3.16 folds), HSP70 (1.06 folds vs. 2.14 folds), and
HSP90 (0.99 fold vs. 2.19 fold) showing statistical signifi-
cance (Figure 3D). Together, these results suggest that
CGCs have a less efficient response to ER stress induced
by glycosylation disruption than CNs.
Among the stress-response proteins studied, the differ-
ence in GRP78/BiP between CGCs and CNs, upon
PMM2 downregulation and TM treatment to disruptglycosylation, was the most striking (Figure 3C,D).
GRP78/BiP is an essential ER chaperone that binds mis-
folded proteins to prevent them from forming aggregates
and its expression is upregulated during ER stress [17].
Upregulation of GRP78/BiP expression is a key target of
the UPR, and is required to alleviate ER stress and pre-
vent ER stress-induced cell death. To further test our
hypothesis that insufficient ER-stress response in CGCs
is the underlying mechanism for the selective neurode-
generation of CGCs in PMM2-CDG, we carried out res-
cue experiments by modulating the levels of GRP78/BiP.
Exogenous GRP78/BiP was overexpressed via an adeno
viral expression system in CGCs, resulting in greater
than 20-fold expression levels of exogenous over en-
dogenous GRP78/BiP (Figure 4A, lanes 1 vs 3). Overex-
pression of GRP78/BiP significantly inhibited caspase-3
activation in CGCs treated with TM (~60%) (Figure 4A,B).
Consistently, the death of CGCs induced by TM treat-
ment was dramatically inhibited upon GRP78/BiP overex-
pression (Figure 4C,D). Likewise, cell death in CGCs
subjected to PMM2 knockdown was significantly reduced
Figure 2 Downregulation of PMM2 results in more cell death in CGCs than in CNs. CGCs and CNs were infected with lentivirus containing
PMM2 or Scrambled control (SC) shRNAs for 3 d. Cells were then subjected to Western blotting and densitometry to determine the protein level
reduction of PMM2, n = 3, *: p < 0.05; **: p < 0.01; ***: p < 0.001 (A); and TUNEL staining to study cell death (B). Dying cells were stained in red
and cell nuclei were stained in blue (with DAPI). C. After TUNEL staining, cell death percentages were quantified. Downregulation of PMM2 led to
increased cell death in both CNs and CGCs, *: p < 0.05; **: p < 0.01; ***: p < 0.001. However, there was considerably more cell death in CGCs than
in CNs. ##: p < 0.01. Please note that during cell culturing, the seeding densities for CNs and CGCs were different. D. CGCs and CNs were infected
with lentivirus containing PMM2 shRNA1 or SC shRNA for 3 d, and then subjected to PMM enzymatic activity assay, n = 3, *: p < 0.05.
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Figure 4E,F). Thus, our findings demonstrate that increas-
ing GRP78/BiP levels in cerebellar neurons can largely, if
not completely, inhibit cell death induced by ER-stress
stimuli.
Discussion
CDGs are a rapidly expanding group of inherited dis-
eases with abnormal glycosylation. Patients with themost common CDG type, PMM2-CDG, develop cerebel-
lar atrophy/hypoplasia, in which significant numbers of
cerebellar Purkinje cells and granule cells are lost.
Herein, for the first time to our knowledge, we provide a
molecular mechanism to explain the selective cerebellar
neurodegeneration in PMM2-CDG patients. We show
that cerebellar neurons are selectively more vulnerable
than cortical neurons to glycosylation defects triggered
either by TM treatment or by PMM2 downregulation.
Figure 3 CGCs and CNs show different ER stress responses to glycosylation disruption induced by PMM2 downregulation or TM
treatments. CGCs and CNs were infected with lentivirus containing PMM2 shRNA1 or scrambled control (SC) shRNA for 3 d (A), or treated with
TM for 3 d (B). Equal amounts of cell lysate proteins were subjected to Western blotting with antibodies against different ER stress-response
proteins. Protein levels were quantified by densitometry. C. Protein level changes upon PMM2 downregulation in A were determined in CNs and
CGCs, respectively. D. Protein level changes upon treatment with 1 ng/mL TM in CGCs and upon 25 ng/mL TM in CNs in B were determined. The
degree of protein level change within CGCs and CNs were compared to one (indicated by dashed lines), n = 3, *: p < 0.05; **: p < 0.01; ***: p < 0.001.
The degree of protein level change between CGCs and CNs were also compared, n = 3, #: p < 0.05; ###: p < 0.001.
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lowing glycosylation disruption seems to be due, at least
in part, to insufficient induction of ER stress-response
proteins, especially GRP78/Bip, a molecule that can pre-
vent the aggregation of misfolded proteins during ER
stress. Accordingly, we demonstrate that increasing
GRP78/Bip levels in cerebellar neurons can largely pre-
vent neuronal death caused by dysregulated glycosyla-
tion. Consistently, genetic disruption of the SIL 1 gene
that encodes a GRP78/BiP co-chaperone in woozy mu-
tant mice leads to protein accumulation, ER stress, and
selective cerebellar neuronal loss; homozygous woozy
mutant mice develop ataxia between 3 and 4 months of
age and have significant loss of cerebellar Purkinje cells
[18]. Furthermore, cells expressing the disrupted yeast
GRP78/BiP ortholog Kar2p lose the ability to respond to
ER stress [19]. Therefore, our results indicate that
GRP78/BiP may be a vital element in restoring ER
homeostasis and cell survival in cerebellar neurons and
a potential target for CDG treatment.When glycosylation was disrupted by TM treatment
and PMM2 downregulation, both percentage of cell
death and GRP78/Bip expression were increased in
CGCs and CNs. However, the increased rates in GRP78/
Bip and other ER-stress response proteins were different
between TM treatment and PMM2 downregulation.
This is probably because TM blocks the synthesis of all
N-linked glycoproteins [13,14] and thus induces strong
ER stress, whereas PMM2 downregulation only inter-
feres with the conversion of mannose-6-phosphate to
mannose-1-phosphate that enters the N-glycosylation
pathway and thus impairs selective glycosylation and
causes a less intensive ER stress.
In addition to PMM2, there are other genes/proteins
that also affect N-linked glycosylation. Phosphomanno-
mutase 1 (PMM1) shares 65% homology to PMM2 and
also converts mannose-6-phosphate to mannose-1-
phosphate [20]. Interestingly, PMM1 is found to be pre-
dominantly present in brain, whereas PMM2 seems to
be ubiquitously expressed [21]; and this raises a
Figure 4 Overexpression of GRP78/Bip rescues CGCs from cell death induced by TM treatment or PMM2 downregulation. CGCs were
infected with GRP78/Bip-overexpressing adenovirus or control (Con) adenovirus 1 d prior to TM treatment (A-D) or PMM2 shRNA downregulation
(E-F). A. Equal amounts of cell lysate proteins were subjected to Western blotting to determine the protein levels of GRP78/Bip and cleaved-
caspase-3. B. Cleaved-caspase-3 levels were quantified by densitometry, n = 3, *: p < 0.05. (C and E) Representative TUNEL staining of CGCs upon
TM treatment or PMM2 shRNA, respectively. Dying cells were stained in red and cell nuclei were stained in blue (with DAPI). (D and F) Quantification
of cell death in C and E, respectively. *: p < 0.05, **: p < 0.01, ***: p < 0.001, comparison between TM- or PMM2 knockdown-treated and untreated
samples. #: p < 0.05, comparison between GRP78/BiP-overexpressing and control samples.
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death and GRP78/Bip expression by glycosylation de-
fects. However, PMM1 has not been found to be associ-
ated with CDG or any other disease. In addition, Pmm1
knockout mice show no observable abnormal pheno-
types as those found in Pmm2 knockout mice [22,23].
These findings imply that PMM1 may not be essential
for normal development. But whether PMM1 and other
proteins mediating N-glycosylation contribute to en-
hanced cell death still deserves further investigation.
Conclusions
CDG patients with PMM2 deficiency have specific cere-
bellar neuron loss. PMM2 converts mannose 6-phosphate
to mannose 1-phosphate that enters the N-glycosylationpathway. Herein we demonstrate that cerebellar neurons
are selectively susceptible to N-glycosylation defects and
this is due to cerebellar neurons’ inefficient response to
ER stress. Our results provide important insight into the




Murine CNs and CGCs were isolated from postnatal day
0 and 7–10 d old C57Bl/6 mice, respectively, and cul-
tured as described previously [24,25]. All procedures
were performed in accordance with the Guide for Care
and Use of Laboratory Animals of the National Institutes
of Health and were approved by the Institutional Animal
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Research Institute.
Analysis of [3H]mannose-labeled glycans
CGCs and CNs were exposed to various concentrations
of TM for 3 d. Glycan synthesis was then studied as de-
scribed previously [26]. Briefly, cells were labeled with
20 μCi/mL [3H]-mannose (Perkin Elmer) for 20 h in the
presence of tunicamycin (TM). After washing with Phos-
phate Buffered Saline (PBS), cells were lysed by sonic-
ation and cellular proteins were precipitated with
trichloroacetic acid. Incorporation of [3H]-mannose in
glycans was measured by liquid scintillation. Three inde-
pendent experiments were carried out and paired t-test
was used for statistical comparison.
TUNEL assay
Cells were fixed with 4% polyformaldehyde at room
temperature for 20 min and permeabilized with 0.2%
Triton X-100 in PBS for 5 min. Cell death was analyzed
using the DeadEnd Fluorometric TUNEL System
(Promega) or Click-iT TUNEL Alexa Fluor Imaging
Assay (Invitrogen), following the manufacturer’s instruc-
tions. The numbers of total and dying cells were counted
from five randomly selected regions and the percent of
cell death was calculated for CNs and CGCs, respect-
ively. Three independent experiments were carried out
and two way factorial ANOVA test was used for statis-
tical analyses.
Pmm2 downregulation
Three short hairpin RNA (shRNA) fragments targeting
murine Pmm2 (5′-GCATACAAAGATGGGAAAC-3; 5′-
GCAGATCTACGGAAAGAGT-3′; 5′-GGTGGCAATG
ACCATGAGA-3′) were cloned into the lentiviral vector
pLentiLox3.7, which contains an EGFP reporter gene. A
scrambled shRNA sequence that does not target any hu-
man or mouse genes was used as control. Lentiviruses
were prepared according to the Lentiviral Expression
System protocol (Invitrogen) and used to transduce
CGCs and CNs.
PMM activity
PMM activity was assayed using a previously described
procedure [27]. The assay was modified by adding glucose-
1,6-bisphosphate instead of mannose-1,6-bisphophate as a
cofactor. Three independent experiments were carried out
and paired t-test was used for statistical analysis.
GRP78/Bip overexpression
GRP78/Bip-overexpressing adenovirus and control ade-
novirus were kindly provided by Dr. Randal Kaufman
(Sanford-Burnham Medical Research Institute). In rescueexperiments, CGCs were infected with the adenovirus one
day before TM treatment or PMM2 downregulation.
Western blotting
After various treatments, cells were lysed and equal
amounts of cell lysate proteins were subjected to SDS-
PAGE and immunoblotting. Antibodies used here
included those against GRP78/BiP (Santa Cruz Biotech-
nology), IRE-1α (Cell Signaling Technology), PDI (Cell
Signaling Technology), cleaved-caspase-3 (Cell Signaling
Technology), heat shock proteins (HSP60, HSP70, and
HSP90) (Assay Designs), α-tubulin (Sigma), β-actin
(Sigma), and PMM2 (Novus). Protein levels were quanti-
tated by densitometry. Three independent experiments
were carried out. For statistical analyses, protein levels
were normalized to those of controls (set as one arbitrary
unit) and paired t-test was used for comparison.
Additional file
Additional file 1: Figure S1. CGCs and CNs show different ER stress
responses upon TM treatments. CGCs and CNs were treated with
indicated amounts of TM for 3 d. Equal amounts of cell lysate proteins
were subjected to Western blotting with antibodies against indicated ER
stress-response proteins. Protein levels were quantified by densitometry
and normalized to those treated with 0 ng/mL TM (set as one arbitrary
units) for comparison. n = 3, error bars: standard deviation.
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